Monoclonal gammopathies

  • 文章类型: English Abstract
    未经证实:由于缺乏有关单克隆丙种球蛋白的信息,我们的主要研究结果是描述流行病学,Souss-Massa地区单克隆丙种球蛋白的临床和生化特征,在摩洛哥南部。
    未经评估:我们进行了一项回顾性研究,只选择完整的医疗记录。我们使用了在当地肿瘤中心诊断为单克隆丙种球蛋白病的患者超过10年的记录。
    未经评估:这项研究纳入了117名患者,男性占比很高(65%),男女性别比为1.85。我们研究人群的平均年龄为61.44(ET14.54)岁。诊断(基于频率)包括:多发性骨髓瘤82.0%(n=96),孤立性浆细胞瘤8.5%(n=10),意义不明的单克隆丙种球蛋白2.6%(n=3),淋巴瘤2.5%(n=3),继发性浆细胞白血病1.7%(n=2),Waldenström病1.7%(n=2)和慢性淋巴样白血病(n=1)。同种型分布如下:IgGκ33.7%(n=28),IgGλ21.7%(n=18),IgAκ12.0%(n=10),IgAλ7.2%(n=6),IgMκ3.6%(n=3),和IgDλ2.4%(n=2)。在两个案例中达到了双峰,比例为2.4%。
    UNASSIGNED:与国际研究相比,由于护理结构中无法使用电泳,因此观察到诊断延迟。
    UNASSIGNED: given the lack of information about monoclonal gammopathies, our primary study outcome was to describe the epidemiological, clinical and biochemical profiles of monoclonal gammopathies in the Souss-Massa region, in southern Morocco.
    UNASSIGNED: we conducted a retrospective study, by selecting only complete medical records. We used records of patients diagnosed with monoclonal gammopathy at the local oncology center during a period of over 10 years.
    UNASSIGNED: one hundred and seventeen patients were included in the study, with a high male predominance (65%) and a male/female sex-ratio of 1.85. The average age of our study population was 61.44 (ET 14.54) years. Diagnoses (based on frequency) included: multiple myeloma 82.0% (n=96), solitary plasmacytoma 8.5% (n=10), monoclonal gammopathies of undetermined significance 2.6% (n=3), lymphoma 2.5% (n=3), secondary plasma cell leukaemia 1.7% (n=2), Waldenström´s disease 1.7%(n=2) and chronic lymphoid leukemia (n=1). The isotype distribution was as follows: IgG Kappa 33.7% (n=28), IgG lambda 21.7% (n=18), IgA Kappa 12.0% (n=10), IgA lambda 7.2% (n=6), IgM kappa 3.6% (n=3), and IgD lambda 2.4% (n=2). Biconal peak was reached in two cases, with a percentage of 2.4%.
    UNASSIGNED: diagnostic delay was observed compared to international studies due to the unavailability of electrophoresis in the care structures.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号